Paper Review Records
全部论文审稿周期
10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
93
天
First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial
作者
Yaning Yang; Wenxin Jiang; Guangjian Yang; Weihua Li; Junling Li; Xuezhi Hao; Puyuan Xing; Siyu Lei; Fang Wei; Linyan Tian; Haiyan Xu; Yan Wang展开收起
作者单位
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Centre de Recherche des Cordeliers, Équipe Labellisée par la Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris 75006, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Institut, Villejuif 94805, France; Department of Respiratory Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China; Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing 100021, China展开收起
56
天
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study
作者
Huaqiang Zhou; Qing Zhou; Qisen Guo; Wei Guo; Gongyan Chen; Zhe Liu; Yun Fan; Yan Li; Yuh-Min Chen; Kenza Bouras; Laurence Del Frari; Angela Guo; Isabelle Klauck; Benoit Sansas; Li Zhang展开收起
作者单位
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong Province, China; Shandong Cancer Hospital, Huaiyin District, Jinan, Shandong Province, China; Shanxi Cancer Hospital, China; Harbin Medical University Cancer Hospital, Heilongjiang, China; Beijing Chest Hospital, Capital Medical University, China; Zhejiang Cancer Hospital, Zhejiang Cancer Center, Hangzhou, China; Chongqing Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, China; Clinical Research Center and Chest Department, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; Pierre Fabre Laboratories, France; Pierre Fabre Laboratories, China展开收起
66
天
Macroscopic on-site evaluation for stratifying the incremental diagnostic benefit of additional sampling during endobronchial ultrasound-guided transbronchial needle aspiration
作者
Tatsuya Imabayashi; Hiroyuki Hashimoto; Yuki Takahashi; Ikuyo Shionoya; Shun Futamura; Sayaka Uda; Tatsuya Yuba; Chieko Takumi; Shinsaku Tokuda展开收起
作者单位
Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Infection Control, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan; Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan展开收起
95
天
Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis
作者
Ruolin Gao; ZhenXiang Li; Jie Huang; Jun Zhao; Yan Wang; Qinxiang Guo; Guangchuan Deng; Hua Bai; Xu Yang; Jianchun Duan; Zhijie Wang; Yuyan Wang; Jingjing Wang; Jiachen Xu; Rui Wan; Boyang Sun; Kailun Fei; Zixiao Ma; Jia Zhong; Jie Wang展开收起
作者单位
State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; Department of Respiratory Medicine, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, TaiYuan, ShanXi 030013, China; Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Tianwen Avenue No. 288, Nan’an District, Chongqing 400010, China展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天